Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 11/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GCKR | Q14397 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349 | 0.92 | GCK (0.38) | GCKPOLBGCKRRORCALDH1A1 | |
| SCHEMBL17033 | 0.84 | GCK (0.46) | GCKGCKR | |
| SCHEMBL16561 | 0.81 | GCK (0.38) | GCKPOLBGCKRRORCTRPV4 | |
| SCHEMBL16588 | 0.80 | GCK (0.30) | GCK | |
| SCHEMBL21749 | 0.79 | RORC (0.39) | GCKGCKRRORC | |
| SCHEMBL17524 | 0.79 | — | — | |
| SCHEMBL17307 | 0.78 | GCK (0.39) | GCKPOLBGCKRRORCALDH1A1 | |
| SCHEMBL16981 | 0.77 | GCKR (0.48) | GCKGCKR | |
| SCHEMBL17195 | 0.77 | — | — | |
| SCHEMBL16486 | 0.73 | GCK (0.30) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |